Last reviewed · How we verify
NCT05695638
Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment
trial in Solid Tumor, Unspecified, Adult in 3,000 participants. Currently enrolling.
31 May 2030
Quick facts
| Lead sponsor | Morten Ladekarl |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 3,000 |
| Start date | 1 July 2020 |
| Primary completion | 31 May 2030 |
| Estimated completion | 31 May 2035 |
| Sites | 1 location across Denmark |
Conditions studied
- Solid Tumor, Unspecified, Adult — all drugs for Solid Tumor, Unspecified, Adult →
- Haematological Malignancy — all drugs for Haematological Malignancy →
Sponsor
Morten Ladekarl
Who can join
18 and older, any sex, with Solid Tumor, Unspecified, Adult or Haematological Malignancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Proseq Cancer is a precision medicine program based on in-house whole exome sequencing (WES) and RNA sequencing. The approved protocol allows for biobanking, registration of clinical and laboratory data, and sharing of genomic data with the purpose of research, while fulfilling the Danish General Data Protection Regulation (GDPR) requirements. Patients are recruited from the North Denmark Region. Treatment can be offered on site if a targeted drug of a nationally approved indication is suggested by the national tumor board (NTB). If not, the patient may be treated in an available clinical protocol. If no approved drug or relevant protocol is available or feasible, treatment with a targeted drug used outside a clinical protocol is pursued.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Longer survival with precision medicine in late-stage cancer patients.
Mapendano CK, Nøhr AK, Sønderkær M, Pagh A, et al · · 2025 · cited 5× · PMID 39754975 · DOI 10.1016/j.esmoop.2024.104089 -
Evaluation of reference sample type for somatic variant calling in myeloid cancers.
Jakobsen MZ, Torp EA, Issa II, Høholt H, et al · · 2025 · PMID 41123648 · DOI 10.1007/s00277-025-06699-y -
Abstracts from the 56th European Society of Human Genetics (ESHG) Conference: Hybrid Posters
· 2024
Verify or expand the search:
- PubMed search for NCT05695638
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Tumor, Unspecified, Adult
Currently open trials in the same condition.
- NCT06911333 — AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT06883539 — A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. · Phase 1 · recruiting
- NCT04942717 — Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values · NA · recruiting
- NCT04932525 — Gustave Roussy Cancer Profiling · NA · recruiting
- NCT04443088 — An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05695638 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Morten Ladekarl
- Last refreshed: 31 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05695638.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing